Zacks Investment Research upgraded shares of Akari Therapeutics PLC (NASDAQ:AKTX) from a sell rating to a hold rating in a research report sent to investors on Monday morning.
According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “
A number of other equities research analysts have also issued reports on the company. ValuEngine raised Akari Therapeutics PLC from a strong sell rating to a sell rating in a research note on Monday, September 11th. Canaccord Genuity reissued a buy rating and set a $15.00 price target on shares of Akari Therapeutics PLC in a research note on Friday, September 22nd. William Blair raised Akari Therapeutics PLC from a market perform rating to an outperform rating in a research note on Friday, September 22nd. Finally, Chardan Capital reissued a neutral rating and set a $2.50 price target (down from $6.00) on shares of Akari Therapeutics PLC in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $8.00.
Akari Therapeutics PLC (NASDAQ:AKTX) opened at $4.38 on Monday. Akari Therapeutics PLC has a 1-year low of $3.18 and a 1-year high of $22.20.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/akari-therapeutics-plc-aktx-upgraded-to-hold-by-zacks-investment-research/1781347.html.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.97% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with our FREE daily email newsletter.